Abstract:Heart failure with preserved ejection fraction(HFpEF) is the most common form of heart failure, and its treatment is still a big challenge in clinic. This paper reviews three hemodynamic mechanisms and three potential molecular mechanisms, respectively. The former includes left ventricular hyperemia(diastolic dysfunction or left atrial hypertension), pulmonary vascular disease(right ventricular dysfunction) and plasma volume expansion. The latter includes systemic microvascular inflammation, cardiac metabolic dysfunction, and cellular(titin) or extracellular(fibrosis) structural abnormalities. In combination with the test results of related drug therapy being completed or in progress, this paper also introduces corresponding therapeutic strategies based on the above pathogenesises. Finally, managerial measures of complications of HFpEF(including myocardial ischemia, atrial fibrillation and hypertension) are briefly introduced.
江雪, 张树龙. 射血分数保留型心衰:机制与治疗的新视点[J]. 实用心电学杂志, 2019, 28(2): 131-135.
JIANG Xue, ZHANG Shu-Long. Heart failure with preserved ejection fraction: a new perspective on the mechanisms and therapies. JOURNAL OF PRACTICAL ELECTROCARDIOLOGY, 2019, 28(2): 131-135.